ASCO Integrates Results from TAILORx into ASCO Clinical Practice Guideline
The ASCO Clinical Practice Guideline was updated to include the results from the TAILORx trial and to provide more specific treatment recommendations.
Diagnosis & Disease Information
OS Benefit of Adding Atezolizumab to Nab-Paclitaxel for Patients With Advanced, PD-L1–Positive Triple-Negative Breast Cancer
Rates of 2-year OS were 51% and 37% in the subgroup of patients with detectable tumor levels of PD-L1 who received atezolizumab and placebo, respectively.
Neratinib Improved PFS Compared With Lapatinib in Pretreated HER2-Positive Metastatic Breast Cancer
Rates of grade 3 diarrhea were 2-fold higher for patient receiving neratinib vs lapatinib, although fewer patients discontinued neratinib due to a treatment-related AE.
Next-Generation Sequencing for Patients: What Test Will I Get?
This fact sheet describes some of the panels used to detect genomic aberrations and guide treatment decisions.
Margetuximab Improved PFS Compared With Trastuzumab in Pretreated Metastatic HER2-Positive Breast Cancer
The Fc fragment of therapeutic antibodies is believed to recognize specific receptors on immune cells and mediate immune functions through this interaction.
Dual Anti-HER2 Neoadjvuant Therapy in HER2-Positive Breast Cancer Should Include Chemotherapy
An exploratory analysis showed higher rates of locoregional progression correlated with lower HER2 expression in tumors.
More Accurate Characterization of Gene Fusion Junctions in Multifocal Lung Cancer Through MPseq
Many standard next-generation sequencing assays require short DNA fragments; this can often limit the resolution of gene rearrangements.
“Real-World” Data Show Improved Outcomes With Personalized Multidrug Therapy: I-PREDICT
Interestingly, 75% of patients with a higher matching score had a longer PFS on their current matched regimen compared with their immediately prior treatment.
An Investigation of the Plasma Metabolome in Patients With Small Cell Lung Cancer
Exposure of patients with small cell lung cancer to platinum-based chemotherapy resulted in altered levels of specific plasma lipids.
Tumor Biopsy Found Less Effective Than Liquid Biopsy for Identifying Resistance Mechanisms in Some GI Cancers
In 78% of patients, circulating cell-free tumor DNA identified a possible mechanism of acquired resistance not identified by standard tumor DNA sequencing.
- Loading...
Loading...
Next post in AACR 2019
Loading... 
Loading...